Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Aug 14, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Aug 6, 2026Quarterly report · 10-QFiled by the company itself.Open the filing ↗
- Aug 6, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record1,41713 flagged findings
Reported transactions (Form 4)77since Mar 29, 2023 · and 1 other holding
Corporate events (8-K)30since Dec 11, 2020
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
What the company does
Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally.
Source: Wikipedia (CC BY-SA 4.0) · copied on Sep 3, 2026 · may not reflect recent changes.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-05-07share offering or dilution eventrecentOpen filing ↗“…398 766 Total $ 4,946 $ 6,863 At March 31, 2026, there was $ 20.9 million of aggregate unrecognized compensation expense related…”
+1 more passage from the same document
- “…1,341,375 $ 0.01 Warrants issued — — Warrants exercised — — Warrants canceled — — Outstanding and exercisable at March 31, 2026…”
- 2026-05-07capital return (buybacks/dividends)recentOpen filing ↗“…of Designation, the shares of Series F-2 and F-4 Preferred Stock are convertible into common stock at the option of the…”
+1 more passage from the same document
- “…common stock at the option of the holder at the conversion price of $ 3.30 per share and $ 6.00 per share, respectively, rounded…”
- 2026-02-26share offering or dilution eventrecentOpen filing ↗“…issued as of December 31, 2025 since the inception of the benefit in 2021. Employees who elect to participate in the ESPP will be…”
+1 more passage from the same document
- “…issued — — Warrants exercised ( 1,615,775 ) 10.00 Warrants cancelled ( 236,125 ) 10.00 Outstanding and exercisable at December…”
- 2026-02-26capital return (buybacks/dividends)recentOpen filing ↗“…our filings with the SEC; • the commencement or outcome of litigation or investigations involving us (or our management), our…”
+1 more passage from the same document
- “…could cause the market price of our common stock to decline and could impair our ability to raise capital through the sale of…”
- 2026-02-26Department of Justice inquiryrecentOpen filing ↗“…Obligations related to information privacy and security (and consumers’ data privacy expectations) are quickly changing, becoming…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
The 25 most recent filings (of 1,417)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Oct 14, 26Form 4 ↗Insider transaction new
- Aug 14, 268-K ↗Current report · Bylaws or fiscal year change
- Aug 6, 2610-Q ↗Quarterly report
- Aug 6, 268-K ↗Current report · Results
- Jul 28, 26SCHEDULE 13G ↗Passive stake · BlackRock, Inc. · 5.3% · event on Jun 30, 26
- May 14, 268-K ↗Current report · A senior executive left or was appointed
- May 7, 2610-Q ↗Quarterly report
- May 7, 268-K ↗Current report · Results
- Apr 27, 26SCHEDULE 13G/A ↗Passive stake · BlackRock, Inc. · 5.0% · event on Mar 31, 26 · amendment
- Apr 2, 26DEFA14A ↗Shareholder meeting and votes
- Apr 2, 26DEF 14A ↗Shareholder meeting and votes
- Mar 20, 26SCHEDULE 13G ↗Passive stake · Daniel Kaufman · 5.1% · event on Mar 18, 26
- Mar 3, 268-K ↗Current report · Other events
- Feb 26, 2610-K ↗Annual report
- Feb 26, 268-K ↗Current report · Results
1,417 filings on record, the oldest from Oct 24, 00.
Listing the 25 most recent filings of the 1,417 on record.
1413281
- May 14, 26A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- May 16, 25A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Mar 21, 25Auditor change filing (8-K Item 4.01)+1 more in the same filing8-K 4.01 ↗
- Jul 19, 24A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Jul 9, 24Listing notice (8-K 3.01)8-K 3.01 ↗
- May 29, 24Listing notice (8-K 3.01)+3 more in the same filing8-K 3.01 ↗
- Apr 26, 24Entered a material agreement8-K 1.01 ↗
- Mar 19, 24Sold unregistered shares+3 more in the same filing8-K 3.02 ↗
4 senior executive changes2023 – 2024show all 4hide
- Mar 19, 24A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Feb 14, 24A senior executive left or was appointed8-K 5.02 ↗
- Jun 13, 23A senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
- Jun 7, 23A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Mar 30, 23Sold unregistered shares+4 more in the same filing8-K 3.02 ↗
- Dec 13, 22Entered a material agreement+3 more in the same filing8-K 1.01 ↗
- Oct 28, 22Listing notice (8-K 3.01)8-K 3.01 ↗
8 older filings not shown · The record reaches back to Dec 1, 04.
Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.
- Jun 16, 20Listing notice (8-K 3.01)+2 more in the same filing8-K 3.01 ↗
- May 2, 19A debt obligation was accelerated+2 more in the same filing8-K 2.04 ↗
- Apr 19, 19A debt obligation was accelerated8-K 2.04 ↗
- Aug 21, 17Listing notice (8-K 3.01)8-K 3.01 ↗
- Feb 15, 17Listing notice (8-K 3.01)8-K 3.01 ↗
- Feb 10, 16Listing notice (8-K 3.01)8-K 3.01 ↗
- Aug 14, 15Listing notice (8-K 3.01)8-K 3.01 ↗
The full record holds 14 stress filings.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13D: stake and stated purpose
Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.
- Rosalind Advisors, Inc.9.9%Dec 31, 25SCHEDULE 13D/A ↗5 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- BlackRock, Inc.5.3%Jun 30, 26SCHEDULE 13G ↗2 earlier filings
- Daniel Kaufman5.1%Mar 18, 26SCHEDULE 13G ↗
- Vivo Opportunity Fund Holdings, L.P.2.2%Mar 31, 25SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
- Mar 6, 26Buy$50KSandra PennellChief Financial Officer↗
- Mar 2, 26Buy$100KGERARD J MICHELCHIEF EXECUTIVE OFFICER↗
- Nov 21, 25Buy$39KJohn Richard Sylvester↗
- Nov 11, 25Buy$98KGERARD J MICHELCHIEF EXECUTIVE OFFICER↗
- Mar 19, 24Buy$100KSTEVEN A J SALAMON↗
- Mar 19, 24Buy$100KGil Aharon↗
- Dec 12, 23Buy$120KVojo VukovicChief Medical Officer↗
- Dec 8, 23Buy$100KGERARD J MICHELChief Executive Officer↗
- Nov 17, 23Buy$73KSandra PennellSVP of Finance, PFO and PAO↗
- Nov 17, 23Buy$240KRosalind Advisors, Inc.↗
- Nov 16, 23Buy$99KDavid L. HoffmanSee Remarks↗
- Nov 16, 23Buy$149KVojo VukovicChief Medical Officer↗
There are 3 more transactions in this stretch.
Stock compensation, tax and giftsshow the 22 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Oct 13, 26Otheramount n/aRosalind Advisors, Inc.↗
- Oct 13, 26Otheramount n/aRosalind Advisors, Inc.↗
- Jun 12, 25Compensation$201KVojo VukovicCHIEF MEDICAL OFFICER↗
- May 5, 25Other$4.0MRosalind Advisors, Inc.↗
- May 5, 25Other$4.0MSTEVEN A J SALAMON↗
- May 5, 25Other$4.0MGil Aharon↗
- Dec 24, 24Other$2.5MRosalind Advisors, Inc.↗
- Dec 24, 24Other$2.5MGil Aharon↗
- Dec 24, 24Other$2.5MSTEVEN A J SALAMON↗
- Oct 22, 24Compensation$100KGERARD J MICHELCHIEF EXECUTIVE OFFICER↗
- Apr 18, 24Otheramount n/aRosalind Advisors, Inc.↗
- Apr 18, 24Otheramount n/aSTEVEN A J SALAMON↗
- Apr 18, 24Otheramount n/aGil Aharon↗
- Apr 18, 24Other$6KRosalind Advisors, Inc.↗
- Apr 18, 24Other$6KSTEVEN A J SALAMON↗
- Apr 18, 24Other$6KGil Aharon↗
- Mar 19, 24Compensation$75KDavid L. HoffmanGEN'L COUNSEL, CCO & SECY↗
- Mar 19, 24Compensation$50KKevin MuirGM INTERVENTIONAL ONCOLOGY↗
- Mar 19, 24Compensation$100KSandra PennellSVP OF FINANCE, PFO AND PAO↗
- Mar 19, 24Compensation$150KGERARD J MICHELCHIEF EXECUTIVE OFFICER↗
- Mar 19, 24Compensation$100KVojo VukovicCHIEF MEDICAL OFFICER↗
- Aug 18, 23Other$140KGERARD J MICHELChief Executive Officer↗
The full record holds 37 transactions and goes back to Feb 8, 23.
Its sector and its market
Delcath Systems Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Delcath Systems Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Delcath Systems Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 1,417 documents on file, from Oct 24, 2000 to Oct 14, 2026.
- Company description
- Wikipedia, read on Sep 3, 2026.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.